Literature DB >> 27230973

Sox2: regulation of expression and contribution to brain tumors.

Sheila Mansouri1, Romina Nejad1, Merve Karabork2, Can Ekinci2, Ihsan Solaroglu2,3, Kenneth D Aldape1, Gelareh Zadeh1,4.   

Abstract

Tumors of the CNS are composed of a complex mixture of neoplastic cells, in addition to vascular, inflammatory and stromal components. Similar to most other tumors, brain tumors contain a heterogeneous population of cells that are found at different stages of differentiation. The cancer stem cell hypothesis suggests that all tumors are composed of subpopulation of cells with stem-like properties, which are capable of self-renewal, display resistance to therapy and lead to tumor recurrence. One of the most important transcription factors that regulate cancer stem cell properties is SOX2. In this review, we focus on SOX2 and the complex network of signaling molecules and transcription factors that regulate its expression and function in brain tumor initiating cells. We also highlight important findings in the literature about the role of SOX2 in glioblastoma and medulloblastoma, where it has been more extensively studied.

Entities:  

Keywords:  SOX2; cancer stem cells; glioblastoma; medulloblastoma; signalling pathways

Mesh:

Substances:

Year:  2016        PMID: 27230973      PMCID: PMC6042636          DOI: 10.2217/cns-2016-0001

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  140 in total

1.  CD133+ niches and single cells in glioblastoma have different phenotypes.

Authors:  Karina Christensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-12-24       Impact factor: 4.130

2.  Core transcriptional regulatory circuitry in human embryonic stem cells.

Authors:  Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

3.  Population-based epidemiologic data on brain tumors in German children.

Authors:  P Kaatsch; C H Rickert; J Kühl; J Schüz; J Michaelis
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

4.  Differential expression of pluripotency factors Sox2 and Oct4 regulate neuronal and mesenchymal lineages.

Authors:  Milad Behbahaninia; Wyatt L Ramey; Maughan K Sindhwani; M Yashar S Kalani
Journal:  Neurosurgery       Date:  2011-10       Impact factor: 4.654

Review 5.  Recent developments and current concepts in medulloblastoma.

Authors:  N U Gerber; M Mynarek; K von Hoff; C Friedrich; A Resch; S Rutkowski
Journal:  Cancer Treat Rev       Date:  2013-12-06       Impact factor: 12.111

6.  Phosphorylation dynamics during early differentiation of human embryonic stem cells.

Authors:  Dennis Van Hoof; Javier Muñoz; Stefan R Braam; Martijn W H Pinkse; Rune Linding; Albert J R Heck; Christine L Mummery; Jeroen Krijgsveld
Journal:  Cell Stem Cell       Date:  2009-08-07       Impact factor: 24.633

7.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

8.  SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

Authors:  Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

9.  MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2.

Authors:  Juan Li; Lutao Du; Yongmei Yang; Chuanxin Wang; Hui Liu; Lili Wang; Xin Zhang; Wei Li; Guixi Zheng; Zhaogang Dong
Journal:  Cancer Lett       Date:  2012-10-27       Impact factor: 8.679

10.  Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 target genes.

Authors:  Brian Boer; Janel Kopp; Sunil Mallanna; Michelle Desler; Harini Chakravarthy; Phillip J Wilder; Cory Bernadt; Angie Rizzino
Journal:  Nucleic Acids Res       Date:  2007-02-25       Impact factor: 16.971

View more
  15 in total

Review 1.  The Clinical and Molecular Characteristics of Sex-Determining Region Y-Box 2 and its Prognostic Value in Breast Cancer: A Systematic Meta-Analysis.

Authors:  Gang Zhao; Xiaozhen Wang; Limei Qu; Zhu Zhu; Jinghui Hong; Haiqin Hou; Zuonong Li; Jun Wang; Zheng Lv
Journal:  Breast Care (Basel)       Date:  2020-03-26       Impact factor: 2.860

2.  THE EXPRESSION OF STEM CELL MARKERS (CD133, NESTIN, OCT4, SOX2) IN INVASIVE PITUITARY ADENOMAS.

Authors:  R Basaran; D Gundogan; M Senol; C Bozdogan; F Gezen; A Sav
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jul-Sep       Impact factor: 0.877

3.  Reduced expression of the murine HLA-G homolog Qa-2 is associated with malignancy, epithelial-mesenchymal transition and stemness in breast cancer cells.

Authors:  Istéfani L da Silva; Lucía Montero-Montero; Ester Martín-Villar; Jorge Martin-Pérez; Bruno Sainz; Jaime Renart; Renata Toscano Simões; Émerson Soares Veloso; Cláudia Salviano Teixeira; Mônica C de Oliveira; Enio Ferreira; Miguel Quintanilla
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

4.  Multinodular and vacuolating neuronal tumors in epilepsy: dysplasia or neoplasia?

Authors:  Maria Thom; Joan Liu; Anika Bongaarts; Roy J Reinten; Beatrice Paradiso; Hans Rolf Jäger; Cheryl Reeves; Alyma Somani; Shu An; Derek Marsdon; Andrew McEvoy; Anna Miserocchi; Lewis Thorne; Fay Newman; Sorin Bucur; Mrinalini Honavar; Tom Jacques; Eleonora Aronica
Journal:  Brain Pathol       Date:  2017-09-19       Impact factor: 6.508

5.  LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.

Authors:  Boyang Liu; Jian Zhou; Chenyang Wang; Yajie Chi; Quantang Wei; Zhao Fu; Changlin Lian; Qiongzhen Huang; Chenxin Liao; Zhao Yang; Huijun Zeng; Ningbo Xu; Hongbo Guo
Journal:  Cell Death Dis       Date:  2020-05-21       Impact factor: 8.469

6.  SOX2 Represses Hepatitis B Virus Replication by Binding to the Viral EnhII/Cp and Inhibiting the Promoter Activation.

Authors:  Hua Yang; Jiayin Mo; Qi Xiang; Peiyi Zhao; Yunting Song; Ge Yang; Kailang Wu; Yingle Liu; Weiyong Liu; Jianguo Wu
Journal:  Viruses       Date:  2020-02-29       Impact factor: 5.048

Review 7.  SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond.

Authors:  Thorsten Schaefer; Claudia Lengerke
Journal:  Oncogene       Date:  2019-09-02       Impact factor: 9.867

Review 8.  Editing SOX Genes by CRISPR-Cas: Current Insights and Future Perspectives.

Authors:  Ali Dehshahri; Alessio Biagioni; Hadi Bayat; E Hui Clarissa Lee; Mohammad Hashemabadi; Hojjat Samareh Fekri; Ali Zarrabi; Reza Mohammadinejad; Alan Prem Kumar
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

9.  Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma.

Authors:  Bülent Polat; Gisela Wohlleben; Rebekka Kosmala; Dominik Lisowski; Frederick Mantel; Victor Lewitzki; Mario Löhr; Robert Blum; Petra Herud; Michael Flentje; Camelia-Maria Monoranu
Journal:  Cancer Cell Int       Date:  2022-02-19       Impact factor: 5.722

10.  Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma.

Authors:  Giulia Maurizi; Narendra Verma; Abhilash Gadi; Alka Mansukhani; Claudio Basilico
Journal:  Oncogene       Date:  2018-05-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.